AARDEX’s scientific lead Bernard Vrijens is a panelist of the FDA and Duke-Margolis public meeting to explore the state of the science of clinical research evaluating medication adherence on December 10, 2019
Medication adherence—the extent to which patients take medications as prescribed in agreement with their health care provider—is an ongoing public health priority, given that improved adherence can lead to better clinical outcomes.
AARDEX is collaborating with Pfizer to implement MEMS® in the FORWARD National Databank for Rheumatic Diseases to derive real world evidence adherence data.
Read more on recent MTX adherence publication
AARDEX’s scientific lead Bernard Vrijens is a co-author of the new publication in the Osteoporosis International journal about determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment.
Discover why the Pharmaceutical world trusts us to resolve patient non-compliance.
Bernard Vrijens, CEO of AARDEX Group, is invited as a guest speaker at the 2019 annual meeting of the ERS, Madrid, Spain, September 30, 2019.
Discover our CEO’s last publication in the British Journal of Clinical Pharmacology
AARDEX Group, the leader in medication adherence monitoring and management
Bernard Vrijens, CEO of AARDEX Group, is invited as a guest speaker at the 2019